MOUNTAIN VIEW, Calif.--(BUSINESS WIRE)--SanBio, a leading regenerative medicine company focused on the discovery and development of cell based biologics, today announced its paper titled “Cell injury-induced release of FGF2: relevance to intracerebral mesenchymal stromal cell transplantations,” has been published in the journal Stem Cells and Development.
“Studies like these move us one step closer to addressing the profound unmet clinical needs of patients suffering from a wide variety of neurological diseases.”
The journal features scientific articles about stem cells and their therapeutic applications and is globally recognized as the trusted source on critical stem cell findings. SanBio’s proprietary cell based product, SB623, has demonstrated the ability to regenerate brain cells after neural damage associated with brain injury in cell cultures and animal models.
This new research focused on one possible mechanism of action that could potentially explain the effects of transplanted mesenchymal stromal cells (MSCs) and SB623 cells (modified MSCs) on surrounding tissue. During transplantation and shortly after, the majority of the transplanted cells usually become injured and die. Scientists found that when MSCs and SB623 cells are injured, they release large amounts of FGF2, a key growth factor for various cells, including neural stem cells and cells forming blood vessels. The strong proliferative signal from dying transplanted cells may increase the regenerative effects of the surviving transplanted cells.
“This is an exciting time in the field of regenerative medicine,” said Damien Bates M.D., Ph.D., MBA, FRACS, SanBio’s Chief Medical Officer and Head of Research. “Studies like these move us one step closer to addressing the profound unmet clinical needs of patients suffering from a wide variety of neurological diseases.”
About SanBio
SanBio is a regenerative medicine company with cell based products in various stages of research, development and clinical trial testing. Its proprietary cell based product, SB623, is in Stage 2 clinical trials for treatment of chronic stroke and is expected to begin Stage 2 clinical trials for treatment of traumatic brain injury later in 2015. Based in Tokyo, the company also has a United States headquarters in San Francisco.
Contacts
For SanBio:
Kris Patrow, 612-455-1748
kris.patrow@padillacrt.com
Help employers find you! Check out all the jobs and post your resume.
